HUTCHMED (China) HCM
NASDAQ HCM
$12.63 +0.07 (+0.56%)
At close: Aug 21, 2026 · 4:00 PM EDT

HUTCHMED (China) (HCM) Non-Current Deffered Revenue (2015 - 2026)

HUTCHMED (China) (HCM) posted quarterly Non-Current Deffered Revenue of $10.6 million for Q2 2026, down 65.64% year-over-year from $30.8 million in Q2 2025, and down 47.46% quarter-over-quarter from $20.1 million in Q4 2025.

HUTCHMED (China) (HCM) Non-Current Deffered Revenue (2015 - 2026) Analysis & Trends

HUTCHMED (China) (HCM) has reported Non-Current Deffered Revenue for 11 consecutive years, with $10.6 million the latest figure, recorded in Q2 2026.

  • In Q2 2026, Non-Current Deffered Revenue fell 65.64% year-over-year to $10.6 million; the TTM figure through Jun 2026 stood at $10.6 million (down 65.64% YoY), while the FY2025 annual figure was $20.1 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue slipped to $10.6 million in Q2 2026 per HCM's latest filing, from $20.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $97.2 million in Q2 2023 and bottomed at $190000.0 in Q4 2022.
  • Historically, Non-Current Deffered Revenue has averaged $36.6 million across 5 years, with a median of $25.5 million in 2025.
  • Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue slumped 37.61% — and 2026, when it slumped 65.64%.
  • HUTCHMED (China)'s Non-Current Deffered Revenue stood at $190000.0 in 2022, then jumped by 51045.26% to $97.2 million in 2023, then tumbled by 37.61% to $60.6 million in 2024, then sank by 66.79% to $20.1 million in 2025, then slumped by 47.46% to $10.6 million in 2026.
  • Business Quant data shows HCM's Non-Current Deffered Revenue at $10.6 million in Q2 2026, $20.1 million in Q4 2025, and $30.8 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Haleon 44.51 Bn 43.55 Bn - -
2 Teva Pharmaceutical Industries 43.52 Bn 39.86 Bn 2.15 Bn -
3 Zoetis 32.43 Bn 30.75 Bn 1.05 Bn -
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn -
5 United Therapeutics 21.87 Bn 19.21 Bn 683.80 Mn -
6 Viatris 18.98 Bn 18.09 Bn 1.46 Bn -
7 Neurocrine Biosciences 15.43 Bn 15.04 Bn 935.80 Mn -
8 Elanco Animal Health 12.02 Bn 11.49 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn - -
10 HUTCHMED (China) 2.19 Bn 2.19 Bn - 10.58 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 10.58 Mn
Dec 31, 2025 20.13 Mn
Jun 30, 2025 30.79 Mn
Jun 30, 2024 60.63 Mn
Jun 30, 2023 97.18 Mn
Dec 31, 2022 190,000.00
Dec 31, 2020 484,000.00
Dec 31, 2019 133,000.00
Dec 31, 2018 408,000.00
Jun 30, 2018 924,000.00
Dec 31, 2017 1.99 Mn
Dec 31, 2016 131,000.00
Dec 31, 2015 2.13 Mn